Cellular Senescence, Senolytics and Autophagy

Why this science gets attention

Three ideas dominate popular talk about the biology of aging: "zombie" cells, cellular self-cleaning and nutrient-sensing pathways. Each is real laboratory science. Each is also used to sell products long before human evidence exists. This page explains the science and keeps it apart from marketing. It is education only: no amounts, no fasting plans and no advice to take any drug.

Evidence labels: approved medicine, established, promising but limited, mixed, insufficient evidence, preclinical (cells or animals only), marketing claim.

Senescence and senolytics

Cellular senescence is a state in which a cell stops dividing but stays alive and releases inflammatory signals, called the senescence-associated secretory phenotype (SASP). [1] Senescence is one of the twelve proposed hallmarks of aging. [2]

Senolytics are treatments meant to remove senescent cells. What human trials show so far:

• In an early, open-label pilot of nine people with diabetic kidney disease, a short course of dasatinib plus quercetin reduced markers of senescent cells in fat tissue and skin and lowered some inflammatory signals. [3] Small, no control group. Label: promising but limited as a biomarker finding.


• In a 2024 randomized trial of 60 postmenopausal women, the same combination did not change the main bone-resorption marker compared with control; exploratory results suggested women with more senescent cells might respond differently. [4]


• A 2026 systematic review found only six completed clinical studies, said safety was generally mild or manageable but that small samples and short follow-up limit judgments, and concluded senolytic and senomorphic approaches should be considered investigational rather than established therapies. [1]

Senolytics are investigational, not established therapies. [1] Products marketed as "senolytic" supplements are marketing claims unless backed by human outcome trials. Proper evidence not found for supplement-only senolytic products: a PubMed search for fisetin senolytic trials returned reviews and a trial protocol but no completed outcome trial.

Autophagy

Autophagy means "self-eating" in Greek: the cell's process for breaking down and recycling its own parts. Yoshinori Ohsumi won the 2016 Nobel Prize in Physiology or Medicine for discovering how it works, using baker's yeast. [5] Label: established as basic biology.

The popular claim is that fasting "turns on autophagy" and slows aging. The research is less settled:

• A 2026 review of intermittent fasting reports that it stimulates cellular repair pathways including autophagy, but also notes inconsistent findings and methodological limits. [6]


• A 2026 muscle review says direct evidence that completed autophagy is impaired in aging human muscle remains limited, and that common lab markers cannot tell the difference between more autophagy and impaired recycling. [7]


• No source we read shows that fasting-induced autophagy extends human life. Label: insufficient evidence.

Metabolic signaling

Cells sense nutrients through pathways including AMPK and mTOR, which intermittent fasting is reported to modulate. [6] "Deregulated nutrient-sensing" is another proposed hallmark of aging. [2]

What people trials show:

A biomarker such as a methylation clock is not a clinical outcome like preventing disease. The CALERIE authors state that conclusive testing needs long-term follow-up on disease and death. [8] The mTOR-targeting medicines are covered under experimental longevity compounds.

Safety and checking first

Fasting is not suitable for everyone; talk with a clinician first if you have diabetes, take glucose-lowering or other medicines, are pregnant or breastfeeding, are underweight, or have a history of disordered eating. Senolytic drug combinations are research-only and carry drug risks. For general guidance see talking with a health professional, mitochondria and oxidative stress and healthy aging research and evidence.